Comparison among proton pump inhibitors
Reading File
Finding Sources
Finding Sources
Searching PubMed
proton pump inhibitors AND pharmacokinetics
Searching the Web
proton pump inhibitors FDA prescribing information omeprazole esomeprazole lansoprazole pantoprazole rabeprazole dexlansoprazole interaction clopidogrel
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Proton pump inhibitors comparison
Reading File
Finding Sources
Finding Sources
Searching PubMed
proton pump inhibitors AND comparative efficacy
Searching the Web
DailyMed proton pump inhibitor omeprazole esomeprazole pantoprazole clopidogrel interaction
Comparison of proton-pump inhibitors (PPIs)
All PPIs are acid-labile prodrugs that irreversibly inhibit the gastric parietal-cell H+/K+-ATPase. At comparable doses, their clinical efficacy for acid-peptic disease is broadly similar. They differ mainly in formulation, CYP2C19 metabolism, interaction potential, cost, and route availability. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 1094.
| PPI | Usual adult once-daily dose for GERD/ulcer* | Distinguishing feature | CYP2C19 interaction / clopidogrel | IV availability |
|---|---|---|---|---|
| Omeprazole | 20-40 mg | Oldest, widely available, inexpensive; immediate-release bicarbonate formulation available | Strong CYP2C19 inhibition. Avoid with clopidogrel. | Yes |
| Esomeprazole | 20-40 mg | S-isomer of omeprazole; higher and more consistent bioavailability | Strong CYP2C19 inhibition. Avoid with clopidogrel. | Yes |
| Lansoprazole | 30 mg | Orally disintegrating tablet and suspension options in some markets | Less interaction than omeprazole, but not the preferred option if clopidogrel is used | No routine IV formulation |
| Dexlansoprazole | 30-60 mg | R-isomer of lansoprazole; dual delayed-release formulation gives prolonged exposure and can be taken without regard to meals | Lower interaction concern than omeprazole/esomeprazole | No |
| Pantoprazole | 40 mg | Common inpatient PPI; relatively low interaction potential | Preferred PPI with clopidogrel in usual practice | Yes |
| Rabeprazole | 20 mg | Relatively more nonenzymatic metabolism; less affected by CYP2C19 genetic variation | Low interaction potential; reasonable with clopidogrel | No |
* Dosing varies substantially by indication, including H. pylori eradication, erosive esophagitis, GI bleeding, NSAID-ulcer prophylaxis, and Zollinger-Ellison syndrome. Do not interchange doses without checking the specific indication.
Pharmacokinetic values and standard doses above are summarized from Katzung's Basic and Clinical Pharmacology, p. 1700.
Practical selection
- On clopidogrel: use pantoprazole most often, or consider rabeprazole. Avoid omeprazole and esomeprazole because they reduce CYP2C19-mediated conversion of clopidogrel to its active metabolite. Current DailyMed clopidogrel labeling specifically advises avoiding omeprazole and esomeprazole.
- Need an IV PPI: pantoprazole, esomeprazole, or omeprazole, depending on local formulary and indication.
- Difficulty timing medicine before meals: dexlansoprazole is convenient because its dual delayed-release formulation is less meal-timing dependent.
- Need low-cost outpatient treatment: generic omeprazole, pantoprazole, or lansoprazole are commonly selected.
- Marked CYP2C19 genetic variability or concern about interactions: rabeprazole and esomeprazole are less dependent on CYP2C19 metabolism than omeprazole, lansoprazole, pantoprazole, and dexlansoprazole.
Administration differences
Most conventional PPIs should be taken 30-60 minutes before breakfast. For twice-daily therapy, give the second dose 30-60 minutes before the evening meal. This timing matters because active proton pumps are most available around meals. PPIs suppress acid for 24-48 hours despite short plasma half-lives, since pump inhibition is irreversible. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, p. 1094.
Class adverse effects
The adverse-effect profile is largely a class effect, not a major basis for choosing among PPIs:
- Common: headache, nausea, abdominal discomfort, diarrhea or constipation.
- With prolonged therapy or higher doses: hypomagnesemia, vitamin B12 deficiency, enteric infections including C. difficile, possible fracture association, and rebound acid hypersecretion after abrupt cessation.
- Reassess the continuing indication periodically and use the lowest effective dose.
One-line exam summary
All PPIs are similarly effective. Pantoprazole is generally preferred with clopidogrel, dexlansoprazole is the most convenient regarding meal timing, and omeprazole is commonly the least expensive but has the most important CYP2C19 interaction concern.
This is a shared conversation. Sign in to Orris to start your own chat.